TY - JOUR
T1 - Clostridioides Infection in Patients with Inflammatory Bowel Disease
AU - Lee, Mi Rae
AU - Kim, Eun Soo
PY - 2022/8/25
Y1 - 2022/8/25
N2 - Inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the gastrointestinal tract, which is often accompanied by altered gut microbial composition. Gut dysbiosis in IBD is considered to be the reason for the high risk of Clostridioides difficile infection (CDI) in patients with IBD. Therefore, CDI should be evaluated in IBD patients with a symptom flare. Medical treatment of non-severe CDI in IBD is similar to that in non-IBD patients and includes oral vancomycin or fidaxomicin. The risk of recurrent CDI in IBD is higher than in non-IBD patients and this could be mitigated by fecal microbiota transplantation. As CDI may worsen the clinical outcomes of IBD, patients should be carefully monitored and an escalation of IBD therapy needs to be considered when there is no improvement seen with the antimicrobial treatment of CDI. This review discusses the risk, pathophysiology, diagnosis, and management of CDI in IBD.
AB - Inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the gastrointestinal tract, which is often accompanied by altered gut microbial composition. Gut dysbiosis in IBD is considered to be the reason for the high risk of Clostridioides difficile infection (CDI) in patients with IBD. Therefore, CDI should be evaluated in IBD patients with a symptom flare. Medical treatment of non-severe CDI in IBD is similar to that in non-IBD patients and includes oral vancomycin or fidaxomicin. The risk of recurrent CDI in IBD is higher than in non-IBD patients and this could be mitigated by fecal microbiota transplantation. As CDI may worsen the clinical outcomes of IBD, patients should be carefully monitored and an escalation of IBD therapy needs to be considered when there is no improvement seen with the antimicrobial treatment of CDI. This review discusses the risk, pathophysiology, diagnosis, and management of CDI in IBD.
KW - Clostridioides difficile infection
KW - Colitis, ulcerative
KW - Crohn disease
KW - Inflammatory bowel diseases
UR - http://www.scopus.com/inward/record.url?scp=85136541097&partnerID=8YFLogxK
U2 - 10.4166/kjg.2022.097
DO - 10.4166/kjg.2022.097
M3 - Review article
C2 - 36004633
AN - SCOPUS:85136541097
SN - 1598-9992
VL - 80
SP - 66
EP - 71
JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
IS - 2
ER -